Adc Therapeutics Sa Stock Performance
| ADCT Stock | USD 4.11 0.21 5.38% |
The firm owns a Beta (Systematic Risk) of 1.15, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ADC Therapeutics will likely underperform. ADC Therapeutics at this moment owns a risk of 4.71%. Please confirm ADC Therapeutics SA potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if ADC Therapeutics SA will be following its current price history.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days ADC Therapeutics SA has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental indicators, ADC Therapeutics is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
Five Day Return 10.17 | Year To Date Return 10.8 | Ten Year Return (86.85) | All Time Return (86.85) |
1 | ADC Therapeutics signals ZYNLONTA peak revenue potential of 600M1B in U.S. with expanded clinical milestones | 11/10/2025 |
2 | ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial | 12/02/2025 |
3 | Disposition of 53236 shares by Carmona Jose of ADC Therapeutics at 3.29 subject to Rule 16b-3 | 12/05/2025 |
4 | Is ADC Therapeutics Stock Outpacing Its Medical Peers This Year | 12/17/2025 |
5 | Is ADC Therapeutics SA stock a contrarian buy - July 2025 Macro Moves Fast Gaining Stock Strategy Reports - ulpravda.ru | 12/19/2025 |
6 | ADC Therapeutics Upgraded to Buy Heres Why | 12/29/2025 |
7 | ADC Therapeutics Announces New Employee Inducement Grant | 01/02/2026 |
8 | INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT | 01/08/2026 |
9 | INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of InvestorsofADC Therapeutics SA - ADCT | 01/13/2026 |
10 | Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT - marketscreener.com | 01/22/2026 |
11 | 170B Patent Cliff Ignites Biotech Deal Wave Late-Stage Platforms Command Premium | 01/30/2026 |
12 | Disposition of 233146 shares by Mallik Ameet of ADC Therapeutics at 3.29 subject to Rule 16b-3 | 02/02/2026 |
| Begin Period Cash Flow | 278.6 M | |
| Total Cashflows From Investing Activities | -867 K |
ADC Therapeutics Relative Risk vs. Return Landscape
If you would invest 416.00 in ADC Therapeutics SA on November 6, 2025 and sell it today you would lose (26.00) from holding ADC Therapeutics SA or give up 6.25% of portfolio value over 90 days. ADC Therapeutics SA is currently generating 0.0037% in daily expected returns and assumes 4.7126% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than ADC, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ADC Therapeutics Target Price Odds to finish over Current Price
The tendency of ADC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 4.11 | 90 days | 4.11 | about 23.35 |
Based on a normal probability distribution, the odds of ADC Therapeutics to move above the current price in 90 days from now is about 23.35 (This ADC Therapeutics SA probability density function shows the probability of ADC Stock to fall within a particular range of prices over 90 days) .
ADC Therapeutics Price Density |
| Price |
Predictive Modules for ADC Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ADC Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ADC Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
ADC Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. ADC Therapeutics is not an exception. The market had few large corrections towards the ADC Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold ADC Therapeutics SA, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ADC Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.21 | |
β | Beta against Dow Jones | 1.15 | |
σ | Overall volatility | 0.33 | |
Ir | Information ratio | -0.04 |
ADC Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ADC Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ADC Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| ADC Therapeutics had very high historical volatility over the last 90 days | |
| ADC Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 70.84 M. Net Loss for the year was (157.85 M) with loss before overhead, payroll, taxes, and interest of (43.18 M). | |
| ADC Therapeutics SA currently holds about 376.78 M in cash with (123.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| ADC Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 233146 shares by Mallik Ameet of ADC Therapeutics at 3.29 subject to Rule 16b-3 |
ADC Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of ADC Stock often depends not only on the future outlook of the current and potential ADC Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ADC Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 97.2 M | |
| Cash And Short Term Investments | 250.9 M |
ADC Therapeutics Fundamentals Growth
ADC Stock prices reflect investors' perceptions of the future prospects and financial health of ADC Therapeutics, and ADC Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ADC Stock performance.
| Return On Equity | -7.06 | ||||
| Return On Asset | -0.24 | ||||
| Profit Margin | (2.22) % | ||||
| Operating Margin | (1.86) % | ||||
| Current Valuation | 365.65 M | ||||
| Shares Outstanding | 123.88 M | ||||
| Price To Earning | 19.80 X | ||||
| Price To Book | 2.58 X | ||||
| Price To Sales | 6.42 X | ||||
| Revenue | 70.84 M | ||||
| Gross Profit | (43.18 M) | ||||
| EBITDA | (102.65 M) | ||||
| Net Income | (157.85 M) | ||||
| Cash And Equivalents | 376.78 M | ||||
| Cash Per Share | 4.90 X | ||||
| Total Debt | 123 M | ||||
| Debt To Equity | 2.75 % | ||||
| Current Ratio | 5.76 X | ||||
| Book Value Per Share | (2.12) X | ||||
| Cash Flow From Operations | (123.83 M) | ||||
| Earnings Per Share | (1.41) X | ||||
| Market Capitalization | 483.12 M | ||||
| Total Asset | 321.98 M | ||||
| Retained Earnings | (1.49 B) | ||||
| Working Capital | 226.92 M | ||||
| Current Asset | 1.11 B | ||||
| Current Liabilities | 288.7 M | ||||
About ADC Therapeutics Performance
Assessing ADC Therapeutics' fundamental ratios provides investors with valuable insights into ADC Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the ADC Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1 K | 1 K | |
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.49) | (0.51) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | 0.70 | 0.74 |
Things to note about ADC Therapeutics performance evaluation
Checking the ongoing alerts about ADC Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ADC Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ADC Therapeutics had very high historical volatility over the last 90 days | |
| ADC Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 70.84 M. Net Loss for the year was (157.85 M) with loss before overhead, payroll, taxes, and interest of (43.18 M). | |
| ADC Therapeutics SA currently holds about 376.78 M in cash with (123.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| ADC Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 233146 shares by Mallik Ameet of ADC Therapeutics at 3.29 subject to Rule 16b-3 |
- Analyzing ADC Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ADC Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining ADC Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ADC Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ADC Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ADC Therapeutics' stock. These opinions can provide insight into ADC Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.